sale price is fixed number of shares in cv1. so if cv1 falls the deal is cheaper right?
I don't like the negative growth in revenues of bright but understandable given covid and their particular market. however if like to know what growth trajectory is ex covid, eg first half of fy20 or even fy19 growth.
price seems expensive given its ebitda result and revenue base. I wonder if there's too much revenue concentration as well, high risk if the business was put up for sale when cracks were showing.
if I read this right, (ex bright here) half year revenues of 7m annualised would be 14m, is this comparable to the floundering 10m we saw in 19 and 20? am I looking at the right figures for comparison? cheers
sale price is fixed number of shares in cv1. so if cv1 falls the...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add KYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $47.69M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 274999 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 19256 | 1 |
View Market Depth
| Last trade - 16.12pm 04/10/2024 (20 minute delay) ? |
| KYP (ASX) Chart |
Day chart unavailable